Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
Amid elevated equity–bond correlations, certain hedge fund styles are likely to improve diversification and limit downside risk, Belle Liang, chief investment officer, CIO & investment advisory, Hang Seng Bank tells FSA.
Sponsored by Loomis Sayles & Natixis
The Growth Equity Strategies Team at Loomis Sayles, an affiliate of Natixis Investment Managers, demonstrates that patience, discipline and conviction result in consistent, peer-leading risk-adjusted compounding over cycles.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
Amid elevated equity–bond correlations, certain hedge fund styles are likely to improve diversification and limit downside risk, Belle Liang, chief investment officer, CIO & investment advisory, Hang Seng Bank tells FSA.
Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
Investors have continued to push positions in tech stocks, emerging markets and North America, while cash hits a new low.
FSA looks at the best performing global equity funds over June and July amidst a volatile unwind of a crowded artificial intelligence trade.
FSA looks at the best performing global equity funds over June and July amidst a volatile unwind of a crowded artificial intelligence trade.
This week FSA compares two Asia Pacific ex-Japan equity funds: the Fidelity Asian Special Situations fund and the JPMorgan SAR Asian fund.
Investors should look beyond fashionable sectors as narrow market leadership leaves quality businesses trading at deeply discounted valuations, says Nitin Bajaj.
Investors should look beyond fashionable sectors as narrow market leadership leaves quality businesses trading at deeply discounted valuations, says Nitin Bajaj.
Sebastian Paredes, head of North Asia and CEO of DBS Bank (Hong Kong), will be retiring from executive duties.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
Hong Kong-headquartered Value Partners Group has announced a plan to establish a yuan-denominated corporate venture capital (CVC) fund focused on artificial intelligence and life sciences.
Value Partners, which was a lead investor in biotechnology firm Insilico Medicine’s Series E financing round, is partnering with Insilico alongside Shanghai Pudong Development and Shanghai Pudong Construction to establish the fund.
Value Partners Private Equity Investment (Shenzhen), the firm’s onshore licensed private fund manager, will act as the fund’s general partner and fund manager.
The firms said they plan to integrate industrial capital and focus on collaborative industrial investments across the “AI + Life Sciences” ecosystem.
Chuen Yan Leung, PhD, partner, private investments, Value Partners Group, said: “Artificial intelligence is transforming the way scientific discoveries are made.”
“The opportunities unlocked by AI for Science (AI4S) extend far beyond the boundaries of any single industry, and life sciences stands out as one of the fields with the highest data density, the most complete validation cycles, and the clearest path to commercialization.”
Alex Zhavoronkov, PhD, founder, co-chief executive officer and chief business officer of Insilico Medicine, said: “Since its founding, Insilico Medicine has built a global operating network and accumulated exploratory experience and practical achievements across multiple AI-enabled life sciences verticals, including small-molecule drugs, biologics, longevity technology, chemistry, brain-computer interfaces (BCI), agriculture, energy and sustainability.”
“Each of these fields holds enormous growth potential and could give rise to the next multi-billion-dollar industry opportunity within AI4S. With the launch of this fund as a starting point, we are initiating a series of incubation and acceleration mechanisms.”
Li Junlan, party committee secretary and chairperson of Pudong Development Group, said he hopes the collaboration will help build a globally influential AI and Life Sciences industrial cluster in Pudong.
Active selection and global diversification can help investors capture attractive credit yields while maintaining quality and flexibility as AI-related issuance reshapes markets, says Sonali Pier.
The multi-boutique investment services firm has hired a global product specialist and an Asia sales director.
The region’s success is based on more than AI and semiconductors.